Clinical Trial Search

Primary: Absolute Change in Total Clinical Score (TCS) of Clinical Signs (Sum of Erythema, Scaling and Infiltration) at End of Treatment Compared to Baseline — -6.00; -4.96…

Primary: Change in the Total Clinical Score From Baseline to Day 22 — -2.8; -1.9; -1.5; -1.8 units on a scale

Primary: Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Week 4 — 2.38; -4.76; 2.48; -4.17 Percent Change

Primary: Change in Total Clinical Score From Baseline to Day 22 — -3.6; -3.7; -4.9; -1.3 units on a scale

Primary: Maintenance of PASI 90 Response at Week 52 in Participants With a PASI 90 Response at Week 24 — 552; 496 Participants — p=0.1499

Primary: Percent Change From Baseline in Psoriasis Assessment of Severity Index (PASI) at Week 12 — -28.043; -37.361 percentage change — p=0.8495

Primary: Percentage Change From Baseline in Psoriasis Scalp Severity Index at Week 12 — 20.4; 86.8 Percent change — p=<0.0001

Primary: Percentage of Participants Achieving Palmoplantar Investigator's Global Assessment (ppIGA) of "Clear" or "Almost Clear" (0 or 1) With at Least a 2-point Reduction From…

Primary: The Absolute Change in Total Clinical Score (TCS) at End of Treatment Compared to Baseline for Daivobet® Ointment — -5.15 Scores on a scale

Primary: Percentage of Participants With Scalp Physician Global Assessment (ScPGA) Score of Clear (0) or Almost Clear (1) With at Least a 2-Point Reduction From Baseline — 13.7…

Primary: Success of Investigator's Global Assessment (IGA) — 3; 7 Participants

Primary: Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 (Defined as at Least 90% Improvement in PASI From Baseline) in Intent to Treat Population at…

Primary: Percentage (%) of Participants Who Achieved Greater Than or Equal (>=) to 75% Improvement From Baseline in Psoriasis Area Severity Index (PASI) Score at Week 12 — 5; 0…

Primary: Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to (≥) 2 Grade/Point Improvement From Baseline at Week…

Primary: Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Week 4 — -53.97; -41.01; -24.26; -17.24 percent change

Primary: Efficacy as Measured by the Mean Percentage Change in the Product of Static Physician Global Assessment (sPGA) and Body Surface Area (BSA). — 53.06; 65.6 percentage of…

Primary: Number of Participants Achieving Success on the Investigator Global Assessment (IGA) Scale — 99; 9 Participants — p=<0.0001

Primary: Mean Percent Change of mNAPSI (Modified Nail Area Psoriasis Severity Index) at Week 36 Compared to Baseline for All Nails. — 64.1 percentage of reduction in mNAPSI score…

Primary: Palmoplantar Psoriasis Physician Global Assessment (PPPGA) of 0 or 1 — 7; 2 Participants

Primary: Percent of Subjects With Treatment Success, Defined by at Least a 2 Grade Improvement From Baseline in the Investigator Global Assessment (IGA) Score Equating to Clear…

Primary: Adrenal Suppression Potential — 16; 18; 5; 3 participants

Primary: Absolute Change in Total Clinical Score (TCS) of Clinical Signs (Sum of Erythema, Scaling, Infiltration) Absolute Change in Total Clinical Score (TCS) of Clinical Signs…

Primary: Change in Total Clinical Score (TCS) of the Clinical Symptoms Compared to Baseline (Day 1) — -1.60; -4.96; -3.04; -3.96 score on a scale — p=<0.001

Primary: Number of Participants With Clinical Improvement of Target Lesions — 18 Participants

Primary: Percentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 75% Reduction (PASI 75) Response at Week 12 — 11.5; 77.8 percentage of…

Primary: Change in Histology

Primary: Treatment Emergent Adverse Events (TEAEs) During the Treatment Phase — 25; 13; 3; 1 participants

Primary: Change From Baseline in Psoriatic Skin Thickness/Echo-Poor Band (EPB) for PF-06263276 4% Solution in Comparison to Corresponding Vehicle at Day 12 — 358.9; 353.1; 17.7…

Primary: The Percentage of Participants With Treatment Success at Week 8 — 45.33; 12.51 percentage of participants

Primary: Percentage of Participants Who Achieved at Least 75 Percent (%) Improvement From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 12 — 5.8; 18.0; 44.2…